Abstract

This month, the UK's High Court ruled in favour of the National Institute for Health and Clinical Excellence decision to limit access to drugs for Alzheimer's disease. But the legal win is unlikely to stem the recent spate of controversies surrounding the institute. Richard Hoey reports.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call